Stocktoria
Black Diamond Therapeutics, Inc. BDTX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-01-30
Chart by TradingView
6/9
Piotroski F — financial health
-0.83
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $70.0M | $0 | — | — | — |
| Operating income | $12.5M | -$78.8M | -$86.5M | -$92.8M | -$126.9M |
| Net income | $22.4M | -$69.7M | -$82.4M | -$91.2M | -$125.6M |
| Operating cash flow | $29.6M | -$62.3M | -$66.7M | -$85.1M | -$100.1M |
| Free cash flow | — | -$62.3M | -$66.8M | -$85.3M | -$102.9M |
| Total assets | $143.0M | $122.6M | $158.6M | $156.3M | $247.7M |
| Total liabilities | $30.8M | $39.4M | $41.8M | $40.6M | $51.8M |
| Shareholders' equity | $112.2M | $83.3M | $116.7M | $115.7M | $195.9M |
| Ratios | |||||
| Operating margin | 17.9% | — | — | — | — |
| Net margin | 32.0% | — | — | — | — |
| Return on assets | 15.6% | -56.8% | -52.0% | -58.3% | -50.7% |
| Return on equity | 19.9% | -83.7% | -70.6% | -78.8% | -64.1% |
| Current ratio | 8.42 | 4.92 | 6.82 | 8.37 | 9.12 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 1,643,747 | $3.5M |
| Point72 Asset Management, L.P. | 100,985 | $215,098 |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.83 (distress)
- Working capital / assets 0.816
- Retained earnings / assets -3.25
- EBIT / assets 0.088
- Equity / liabilities 3.643
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001701541 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.